O22: CONJUGATED IRON NANOPARTICLES AS THERAPEUTIC CARRIERS FOR SPECIFIC TARGETING OF CANCER CELLS

Abstract Introduction Precision medicine with minimal side effects remains the goal of cancer therapy. Iron oxide nanoparticles are non-toxic, successful carriers substances, targeting tissues and delivering high payloads conjugated agents. Interfering RNA (siRNA) disrupts protein expression, an effective treatment e.g. for hereditary amyloidosis. This study tested transferrin-conjugated dopamine-coated iron nanoparticle (TF-dpFe3O4) delivery siRNA to cells overexpressing transferrin receptor (TFR). Method Cells were cultured in FBS-DMEM/F12. Fe3O4 prepared by co-precipitation, dopamine coated +/- conjugation. LDH/MTT assays assessed cell viability responses [TF-dpFe3O4] or [dpFe3O4]. Protein expression was examined PAGE, densitometry immunofluorescence. Targeting efficacy determined MEK2 gene silencing using siRNA-conjugated TF-dpFe3O4 dpFe3O4. Result T-47D expressed levels TFR MEK2. No significant effect on observed ≤2.5mg/mL By conventional transfection, 10nM lowered 25% (48hr); rebounded 50% 72hr. (2.5mg/mL) reduced (72hr) without rebound; a-tubulin (control) unaffected. In contrast, as decreased, increased 2.2-fold (72hrs). Conclusion safe/efficient vehicles over-expressing TFR. Over 72hrs, 50%, a target superior methods. Notably: MAPK pathway inhibited, increases observed, suggesting adaptations damage stress. Take-home message safe efficient vehicle TFR, allowing inhibition proteins, such MEK2, that drive tumour growth.